EP3983809A4 - Biothiolaktivierbare sonde und verfahren zur verwendung - Google Patents

Biothiolaktivierbare sonde und verfahren zur verwendung Download PDF

Info

Publication number
EP3983809A4
EP3983809A4 EP20827233.6A EP20827233A EP3983809A4 EP 3983809 A4 EP3983809 A4 EP 3983809A4 EP 20827233 A EP20827233 A EP 20827233A EP 3983809 A4 EP3983809 A4 EP 3983809A4
Authority
EP
European Patent Office
Prior art keywords
biothiol
activated probe
probe
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20827233.6A
Other languages
English (en)
French (fr)
Other versions
EP3983809A1 (de
Inventor
Jie Zheng
Xingya JIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of EP3983809A1 publication Critical patent/EP3983809A1/de
Publication of EP3983809A4 publication Critical patent/EP3983809A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD or ATP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
EP20827233.6A 2019-06-17 2020-06-17 Biothiolaktivierbare sonde und verfahren zur verwendung Withdrawn EP3983809A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862484P 2019-06-17 2019-06-17
PCT/US2020/038045 WO2020257224A1 (en) 2019-06-17 2020-06-17 Biothiol-activatable probe and method of use

Publications (2)

Publication Number Publication Date
EP3983809A1 EP3983809A1 (de) 2022-04-20
EP3983809A4 true EP3983809A4 (de) 2023-04-19

Family

ID=74037318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20827233.6A Withdrawn EP3983809A4 (de) 2019-06-17 2020-06-17 Biothiolaktivierbare sonde und verfahren zur verwendung

Country Status (6)

Country Link
US (1) US12440582B2 (de)
EP (1) EP3983809A4 (de)
JP (1) JP2022536937A (de)
KR (1) KR20220041074A (de)
CN (1) CN114641691A (de)
WO (1) WO2020257224A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981896B (zh) * 2019-12-17 2022-07-01 南宁师范大学 11-巯基十一烷酸修饰的金纳米簇的制备方法及其应用
CN117337194A (zh) * 2020-08-24 2024-01-02 德克萨斯州大学系统董事会 包含与吲哚菁绿缀合的聚乙二醇的组合物及其使用方法
US20260191997A1 (en) * 2021-10-25 2026-07-09 Board Of Regents, The University Of Texas System Conjugates having antifouling nanoparticles and methods of use
CN116514901B (zh) * 2023-07-04 2023-09-29 北京建工环境修复股份有限公司 一种双响应荧光铁纳米簇探针及其制备方法和应用
CN119241417B (zh) * 2024-08-05 2025-10-14 四川大学华西医院 同时检测γ-谷氨酰转肽酶和过氧亚硝酸盐的探针及制法
CN119978031B (zh) * 2025-02-14 2026-02-24 厦门大学 基于铂类化疗药物的分子探针制备及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228344B1 (en) 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
US5928625A (en) 1997-03-13 1999-07-27 Mallinckrodt Inc. Method of measuring physiological function
US9549998B2 (en) * 2007-06-28 2017-01-24 The Curators Of The University Of Missouri Stabilized gold nanoparticle and contrast agent
AU2009221976B2 (en) * 2008-03-03 2014-02-27 Kansas State University Research Foundation Protease assay
EP2609935B1 (de) 2010-08-23 2018-10-10 Shimadzu Corporation Umschaltung einer sonde mit fluoreszierenden nanopartikeln sowie verfahren zur abbildung fluoreszierender nanopartikel damit
US9295685B2 (en) 2011-02-24 2016-03-29 Omeros Corporation Mixed micelles
AU2012302089A1 (en) 2011-08-29 2014-04-17 Cardiox Corporation System for non-invasive assay of liver function
CN103990138B (zh) 2013-05-21 2017-04-19 中国人民解放军第二军医大学 逐层组装纳米金复合物递药载体系统及其制备方法和应用
CN103721271B (zh) 2013-12-17 2015-06-17 福州市传染病医院 用于肝癌多模态影像和光热治疗的多功能纳米探针及应用
WO2017184924A1 (en) 2016-04-22 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Synthesis of water-soluble thiolate-protected gold nanoparticles of uniform size and conjugates thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU HUI ET AL: "A gold nanocluster-based ratiometric fluorescent probe for cysteine and homocysteine detection in living cells", NEW JOURNAL OF CHEMISTRY, vol. 41, no. 11, 1 January 2017 (2017-01-01), GB, pages 4416 - 4423, XP093004240, ISSN: 1144-0546, DOI: 10.1039/C6NJ04134E *

Also Published As

Publication number Publication date
JP2022536937A (ja) 2022-08-22
US12440582B2 (en) 2025-10-14
WO2020257224A1 (en) 2020-12-24
CN114641691A (zh) 2022-06-17
US20220241439A1 (en) 2022-08-04
KR20220041074A (ko) 2022-03-31
EP3983809A1 (de) 2022-04-20

Similar Documents

Publication Publication Date Title
EP3758575A4 (de) Endoskop und verfahren zur verwendung
EP3749343A4 (de) Formulierung und verfahren zur verwendung
EP3952721A4 (de) Endoskop und verfahren zur verwendung
EP4030422A4 (de) Sprachinteraktionsverfahren und -vorrichtung
MA53919A (fr) Constructions d'acides nucléiques et procédés d'utilisation
EP3801166A4 (de) Zusammenklappbare schneeschaufel und verfahren zur verwendung
EP3860477A4 (de) Endoskop und verfahren zur verwendung
EP3962479A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP3962481A4 (de) Kcnt1-hemmer und verfahren zur verwendung
EP3982238A4 (de) Schnittstellenerzeugungsverfahren und -vorrichtung
EP3694390A4 (de) Endoskop und verfahren zur verwendung
EP3768078A4 (de) Vorrichtung und verfahren zur steuerung von tierpositionen
EP3586207A4 (de) Planung und anpassung von projekten auf der basis einer baubarkeitsanalyse
EP3709910A4 (de) Endochirurgische vorrichtung und verwendungsverfahren
EP4068648A4 (de) Anzeigeverfahren und -vorrichtung
EP4069726A4 (de) Glp2-rezeptoragonisten und verfahren zur verwendung
EP3951845A4 (de) Inspektionsvorrichtung und inspektionsverfahren
EP3810615A4 (de) Arginase-inhibitoren und verfahren zur verwendung
EP3765006A4 (de) Arginasehemmer und verfahren zur verwendung
EP3635114A4 (de) Herstellung und verwendung von guide-nukleinsäuren
EP3969460A4 (de) Ascarosidderivate und verfahren zur verwendung
EP3996714A4 (de) Formulierungen von rbp4-inhibitoren und verwendungsverfahren
EP4040292A4 (de) Verfahren zur ns-instantiierung und nfvo
EP3873319A4 (de) Medizinische vorrichtung mit reflow-einschlussankern und verfahren zu deren verwendung
EP3765005A4 (de) Inhibitoren von integrin alpha 2 beta 1 und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20221209BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230321

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20230315BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20250721